Cobicistat, elvitegravir and the Quad are investigational products and their safety and efficacy have not yet been established.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.
This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the risk that Gilead may fail to obtain approvals for cobicistat and Quad from regulatory authorities and any marketing approval, if granted, may have significant limitations on their use. As a result, cobicistat and Quad may never be successfully commercialized. In addition, Gilead may make a strategic decision to discontinue development of cobicistat or Quad if, for example, it believes commercialization will be difficult relative to other opportunities in its pipeline. Further, Gilead may be unsuccessful in developing and commercializing fixed-dose combinations that combine cobicistat with other protease inhibitors, including darunavir and atazanavir. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
U.S. full prescribing information for Truvada is available at
Truvada is a registered trademark of Gilead Sciences, Inc.
For more information on Gilead Sciences, please visit the company’s website at
, follow Gilead on Twitter (
) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.